低对比剂剂量CTA对TAVR装置尺寸选择及入路血管评估的影响
该研究评估低对比剂剂量成像对TAVR术前测量的影响及双源CT后对比剂急性肾损伤发生率。慢性肾病患者低对比剂方案图像质量良好但观察者间测量一致性较低,导致更多瓣膜尺寸和经股动脉入路判断分歧;肾功能无恶化,无对比剂急性肾损伤发生。
要点
- 慢性肾病患者低对比剂剂量CTA图像质量良好但低于标准剂量,观察者间测量一致性仍优秀。
- 低对比剂组瓣膜尺寸判断分歧5/25,标准剂量组0/25;经股动脉入路判断分歧4/25对2/25。
- 低对比剂双源CT在慢性肾病患者中似乎安全,未见肾功能恶化或对比剂急性肾损伤。
诊断标准与关键数值
- 慢性肾病低对比剂组(N=25)对比剂中位68 mL [52-87]、管电压中位90 kV [80-90]、SCr中位1.6 mg/dL [1.5-1.9];非慢性肾病标准对比剂组对比剂中位116 mL [96-134]、管电压中位100 kV [90-110]、SCr中位1.0 mg/dL [0.9-1.1](P<0.00)。
- 低对比剂组图像质量良好但低于标准对比剂组(P<0.02)。
- 观察者间测量可靠性优秀(ICC>0.85)。
- 低对比剂组观察者间一致性较低,导致瓣膜尺寸判断分歧5/25(kappa 0.73),标准对比剂组0/25(kappa 1.00);经股动脉入路合格性判断分歧低对比剂组4/25(kappa 0.68),标准对比剂组2/25(kappa 0.84)。
- 低对比剂TAVR队列(N=35)1个月SCr平均变化-1% [-12至+7%],标准对比剂组(N=118)0% [-8至+10%](P>0.3),对比剂急性肾损伤发生0例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Chronic kidney disease (CKD) is prevalent in transcatheter aortic valve replacement (TAVR) candidates, leading to concerns regarding contrast medium (CM) safety. We evaluated (a) the impact of low-CM imaging on pre-TAVR measurements and (b) postcontrast acute kidney injury (PC-AKI) prevalence after dual-source computed tomography (DSCT) in TAVR candidates.
METHODS: All TAVR candidates with CKD (SCr≥1.5 mg/dL) who underwent weight-based low-CM, low-pitch helical 3rd-generation DSCT in a one-year period were included, and matched to standard-CM, non-CKD controls (N = 50). Image quality (IQ) and pre-TAVR measurement interobserver variability were evaluated. Renal function change and PC-AKI were studied in the entire TAVR cohort, irrespective of scan mode (N = 153).
RESULTS: Low-CM in CKD (N = 25) was performed with median 68 mL CM [52-87], 90 kV [80-90] and SCr 1.6 mg/dL [1.5-1.9], and standard-CM without CKD with median 116 mL CM [96-134], 100 kV [90-110] and SCr 1.0 mg/dL [0.9-1.1](P < 0.00). Low-CM IQ was good, though lower compared with standard-CM (P < 0.02). Interobserver measurement reliability was excellent (ICCs>0.85). Interobserver-agreement was lower in low-CM, causing prosthesis size disagreement in 5/25 (kappa-0.73) versus 0/25 with standard-CM (kappa-1.00), and transfemoral eligibility disagreement in 4/25 (kappa-0.68) versus 2/25 (kappa-0.84), respectively. Mean 1-month SCr-change in the low-CM TAVR cohort (N = 35) was -1 % [-12 to +7 %] and in standard-CM (N = 118) 0 % [-8 to +10 %](P > 0.3). PC-AKI occurred in none.
CONCLUSION: Low-CM third-generation-DSCT achieves good IQ in TAVR candidates with CKD, and seems safe, with no apparent renal function deterioration or prevalence of PC-AKI. However, standard-CM protocols in non-CKD patients provide higher measurement reproducibility. Low-CM protocols should therefore be reserved for patients at high risk for PC-AKI.
引用
- Suchá D, Kino A, Bogart K, et al. Effect of low contrast medium-dose CTA on device sizing and access vessel assessment for TAVR. Eur J Radiol. 2020. PMID: 32000074. doi:10.1016/j.ejrad.2020.108826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。